EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, OraSure Technologies's enterprise value is $143.9 Mil.
OraSure Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $405.5 Mil. Therefore, OraSure Technologies's EV-to-Revenue for today is 0.35.
The historical rank and industry rank for OraSure Technologies's EV-to-Revenue or its related term are showing as below:
OSUR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.29 Med: 2.58 Max: 8.69
Current: 0.35
During the past 13 years, the highest EV-to-Revenue of OraSure Technologies was 8.69. The lowest was 0.29. And the median was 2.58.
OSUR's EV-to-Revenue is ranked better than 92.73% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 3.07
vs OSUR: 0.35
OraSure Technologies EV-to-Revenue Historical Data
The historical data trend for OraSure Technologies's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OraSure Technologies's EV-to-Revenue
For the Medical Instruments & Supplies subindustry, OraSure Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OraSure Technologies's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where OraSure Technologies's EV-to-Revenue falls into.
OraSure Technologies's current Enterprise Value is $143.9 Mil.
OraSure Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $405.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OraSure Technologies's share price for today is $5.26.
OraSure Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OraSure Technologies EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of OraSure Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
OraSure Technologies (OraSure Technologies) Business Description
OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSUR has been successfully added to your 